Abstract: A clear personal care composition includes water, a volatile silicone, and a silicone polyether having a molecular weight greater than 1000 and an HLB greater than 4. The composition may be, for example, an antiperspirant or deodorant composition.

Abstract: The present invention relates to a deodorant composition, in particular a cosmetic composition, comprising, as odor-absorbing agent, at least one water-soluble zinc salt, and preferably zinc pyrrolidonecarboxylate, to the use of the composition for the manufacture of cosmetic products intended for human topical application, in particular deodorants, to a process for treating human axillary smells, and to the use of a water-soluble zinc salt as, preferably sole, an odor-absorbing agent in a deodorant composition. The composition is particularly intended for formulations comprising an aqueous phase: aqueous lotions, emulsions and preferably water-in-silicone emulsions.

Abstract: A new method for the inhibition of human sweating and body malodour is described. An agent capable of blocking calcium channels in the secretory coil cells of human sweat glands is topically applied; on reaching the secretory coil cells, the action of this agent results in reduced sweat production. Preferred agents are natural plant extracts. The transport of the agent to the secretory coil is preferably enhanced in some way, for example by iontophoresis or the use of a skin penetration enhancer. Antiperspirant products comprising a calcium channel blocking agent and a pore-blocking antiperspirant active are also claimed.

Abstract: Disclosed are viscoelastic compositions and methods of their use in surgical and non-surgical packing and in effecting drug delivery, especially in conjunction with trauma to of disorders of the ear.

Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3 -L finds use in treating patients with anemia, AIDS and various cancers.

Abstract: The present invention relates to processes for the purification of proteins. More specifically, methods for solubilizing and purifying proteins expressed in an insoluble form using low concentrations of chaotropic agents, such as guanidine salts, are provided. Also provided are methods for refolding proteins solubilized according to the present invention.

Abstract: The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions containing hybrid molecules.

Abstract: The present invention relates to methods and compositions for delivering a nucleic acid to motor neurons administering the nucleic acid to muscle tissue. The invention relates to methods for treating pathologies of the nervous system, such as trauma and neurodegenerative diseases.

Abstract: Methods and compositions are disclosed which comprise red rice fermentation products, that can be used as natural dietary supplements and/or medicaments for the treatment or prevention of hyperlipidemia and associated disorders and symptoms, such as cardiovascular diseases, cerebrovascular diseases, diabetes, hypertension, obesity, asthenic breathing, chronic headache, chest pain and tightness, limb swelling and distention, loss of appetite and excess expectoration. The methods and compositions are effective in lowering both the serum cholesterol and serum triglyceride levels in humans, and can be used for maintaining cardiovascular health. The invention also encompasses particular Monascus strains that yield fermentation products with the desired biological activities.

Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.

Abstract: Compositions and methods which ameliorate the virulence of bacterial infection are described wherein the active ingredient modulates transmethylation reactions in bacterial cells. Particularly useful compounds are inhibitors of S-adenosyl methionine synthetase (SAMS), of S-adenosyl homocysteine hydrolase (SAHH) and of transmethylases.

Abstract: The present invention relates to an anti-idiotypic antibody or antigen-binding fragment against FimH adhesin of uropathogenic Type I-fimbriated Escherichia coli and an immunizing composition containing such an anti-idiotypic antibody or antigen-binding fragment thereof as an active immunizing component. The present invention also relates to a method for stimulating and enhancing the production of antibodies which recognize and bind to FimH of uropathogenic Type-I-fimbriated Escherichia coli, but not to FimH of non-uropathogenic Type I-fimbriated Escherichia coli.

Abstract: This invention is directed to a Directed Human Immunoglobulin and compositions thereof for preventing or treating staphylococcal infections such as S. epidermidis.

Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

Abstract: An antigenic preparation is provided containing an outer membrane protein associated with pathogenic strains of Leptospira. The protein has been designated ALipL32″ for Alipoprotein from Leptospira≅ and because the isolated polypeptide migrates to a position corresponding to a molecular weight of 32 kD in a denaturing polyacrylamide gel. The invention provides polynucleotides encoding LipL32 and antibodies that bind the protein which are useful in the diagnosis of leptospirosis. In addition, LipL32 can be used immunologically as a vaccine for spirochete-associated pathologies.

Abstract: We have screened the HCMV-specific T cell clone, 33F4, with a nonamer PS-SCL based on SEQ ID NO: 1, and described a series of analog peptides that are recognized with greater affinity than the native peptide sequence.

Abstract: The invention provides compositions and methods for modulating immune responses in subjects. The invention is based, at least in part, on the discovery that an in-frame translation fusion of an antigen with an APC binding domain of an opsonin forms a molecule, that is, a fusion polypeptide, which when administered to a subject modulates an immune response to the antigen.

Abstract: The present invention relates to a polysaccharide-protein conjugate. The invention also relates to a method of using the conjugate to prevent systemic infections. The invention further relates to a pharmaceutical composition. The invention also relates to a method of producing a polysaccharide-protein conjugate.

Abstract: Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. The DNA of the recombinant viruses can be used as probes or for generating PCR primers.

Abstract: The present invention relates to a method of producing a vaccine for the prevention of F. necrophorum bacterial infections, comprising isolating the F. necrophorum bacteria from a bovine species, growing the bacteria in a suitable growth medium for a period equal to between about 10 hours and about 18 hours so as to achieve a bacterial population equal to at least 1×105 CFU/ml, terminating the growth, and using a whole cell culture to form the vaccine. Additionally, the present invention relates to the vaccine comprised of a killed whole cell population of the F. necrophorum bacteria taken from a bovine. The present invention further relates to a method for preventing footrot and liver abscesses caused by F. necrophorum bacteria.

Abstract: A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the treatment of hypersecretion of mucus, which inhibits mucus secretion by inhibiting mucus secreting cells, and/or inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.

Abstract: This invention is directed to mutant SPE-A toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-A toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-A toxin. The mutant SPE-A toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-A toxin.

Abstract: An intumescent polymer composition includes a matrix polymer, an acid catalyst source, a nitrogen source and an ionic phyllosilicate synergist having substantial cationic exchange capacity.

Abstract: Water-soluble compositions comprising a lipophilic compound and a solubilizing agent of the general formula: {X—OOC—[(CH2)n—COO]m}p—Y  (I) wherein: X is a residue of a hydrophobic moiety, Y is a residue of a hydrophilic moiety, p is 1 or 2, m is 0 or 1, and n is an integer greater than or equal to 0 are disclosed. The lipophilic compound is preferably selected from the group consisting of water-insoluble ubiquinones, ubiquinols, vitamins, provitamins, polyene macrolide antibiotics, and mixtures thereof. The hydrophobic moiety is preferably a sterol or a tocopherol and the hydrophilic moiety is preferably a polyalkylene glycol. In some embodiments, the sterol is cholesterol or sitosterol, the tocopherol is &agr;-(+)-tocopherol, the polyalkylene glycol is a polyethylene glycol or its methyl monoether having an average molecular weight between 400 and 1000, p is equal to 1 or 2, m is equal to 0 or 1 and n is an integer between 2 and 18.

Abstract: Cosmetic compositions containing ferulic acid at a pH of from 3 to 5, in an aqueous phase, along with a polyol, have improved storage stability and dissolution at body temperature.

Abstract: The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intracellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D-&agr;-tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses.

Abstract: Water soluble macromers are modified by addition of free radical polymerizable groups, such as those containing a carbon-carbon double or triple bond, which can be polymerized under mild conditions to encapsulate tissues, cells, or biologically active materials. The polymeric materials are particularly useful as tissue adhesives, coatings for tissue lumens including blood vessels, coatings for cells such as islets of Langerhans, and coatings, plugs, supports or substrates for contact with biological materials such as the body, and as drug delivery devices for biologically active molecules.

Abstract: This invention relates to the chemoprevention of prostate cancer and, more particularly, to a method of suppressing or inhibiting latent prostate cancer comprising administering to a mammalian subject a chemopreventive agent and analogs and metabolites thereof. The chemopreventive agent prevents, prevents recurrence of, suppresses or inhibit prostate carcinogenesis; and treats prostate cancer.

Abstract: Processes for conveniently and economically producing L-arabinose, enzyme-treated products containing L-arabinose, diet foods and diabetic foods containing L-arabinose with dietary fiber, and fruit or vegetable juices containing L-arabinose are provided. (1) A process for producing L-arabinose by treating a natural material containing arabinan, arabinoxylan or arabinogalactan with an enzyme having an activity of acting on natural substances containing arabinan, arabinoxylan or arabinogalactan and thus releasing L-arabinose to give L-arabinose, characterized in that the above-described natural substance is directly treated with the above-described enzyme without separating or extracting arabinan, arabinoxylan or arabinogalactan.

Abstract: The present disclosure is directed to compositions containing boron which are useful for a variety of purposes, including enhancing bone health, alleviating arthritis, pain, and inflammation, and producing other beneficial health effects. The disclosure is further directed to methods of preparing such compositions, methods of using (including administering) the compositions, and kits comprising the compositions. The compositions have a pH which is at least about 2 pH units less than the pKa of the boron compound.

Abstract: This invention relates to a method for producing an adherable biomaterial patch. The subject patch is capable of being joined onto a tissue substrate. The invention is also directed to the patch per se, and to a method for producing the adherable biomaterial patch which is joined onto a tissue substrate. A preferred patch can even function in a highly acidic environment. The method of the present invention comprises providing a biomaterial patch consisting essentially of elastin or an elastin-based biomaterial having at least one outer surface. Next, at least one outer surface of the biomaterial patch is treated with a selected cyanoacrylate adhesive to produce a adherable biomaterial patch.

Abstract: A two pulse gastrointestinal delivery system is provided. The system comprises a desired agent in combination with a swellable core material, the core being surrounded by an inner coat of a water-insoluble or relatively water-insoluble coating material in which particulate water-insoluble material is embedded. The inner coat is additionally surrounded by an outer coat that contains additional amounts of the desired agent. When the delivery device enters the gastrointestinal tract, the outer coat releases the desired agent contained therein and disintegrates, exposing the inner coat. The particulate matter in the inner coat takes up liquid, thus forming channels interconnecting the drug-containing core with the outside of the delivery device. Through these channels liquid enters the core which then swells to the point at which the inner coat is broken. When the integrity of the inner coat is destroyed, the core then disintegrates, immediately releasing all or most of the drug at a specific site.

Abstract: Coloring change of a pharmaceutical composition containing a compound having a phenolic hydroxyl group, such as an anti-inflammatory agent or an antioxidant having a phenolic hydroxyl group or the compound of formula (I) can be controlled by adding an acid. The present invention provides a pharmaceutical composition containing a compound having a phenolic hydroxyl group and an acid in which coloring change is controlled.

Abstract: An antibiotic product for delivering at least Ciprofoxacin or Metronidazole that is comprised of three dosage forms with different release profiles with each of Ciprofoxacin and Metronidazole being present in at least one of the dosage forms.

Abstract: The invention relates to the use of a multilayer pharmaceutical product that substantially comprises a) a core containing a pharmaceutically active substance, b) an inner coating consisting of a copolymer or a mixture of copolymers that are composed of 85 to 98 wt.- % of radically polymerized C1 to C4 alkyl esters of the acrylic or methacrylic acid and 15 to 2 wt.- % of (meth)acrylate monomers with a quaternary ammonium group in the alkyl group, and c) an outer coating consisting of a copolymer that is composed of 75 to 95 wt.- % of radically polymerized C1 to C4 alkyl esters of the acrylic or methacrylic acid and 5 to 25 wt.- % of (meth)acrylate monomers with an anionic group in the alkyl group. The inventive product is used for producing a pharmaceutical product that releases the active substance contained therein according to the USP release test, at pH 1.2 during 2 hours and subsequent rebuffering to pH 7.0, by less than 5% after 2.

Abstract: A molecular dispersion composition is disclosed. The molecular dispersion comprises a compound of the formula: molecularly dispersed in a polymer matrix. Also disclosed are solid dosage forms, e.g., tablets and capsules, containing these molecular dispersions.

Abstract: A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhalation in which at least 50% of the total mass of the active compounds consists of primary particles having a diameter less than or equal to about 10 microns, the primary particles optionally being formed into agglomerates.

Abstract: Compositions and methods are provided to control the release of relatively low molecular weight therapeutic species through hydrogels by first dispersing or dissolving such therapeutic species within relatively hydrophobic rate modifying agents to form a mixture. The mixture is formed into microparticles that are dispersed within bioabsorbable hydrogels, so as to release the water soluble therapeutic agents in a controlled fashion. Methods of using the compositions of the present invention in therapeutic systems are also provided.

Abstract: A cruciferous plant, cut pieces thereof, and juice of the plant and the cut pieces are subjected to at least one treatment selected from the group consisting of anaerobic treatment, 25 to 50° C. thermal retention treatment, and glutamic acid treatment, to enrich &ggr;-aminobutyric acid (GABA), thereby obtaining a cruciferous plant, cut pieces, and juice containing GABA in various concentrations. By performing microwave radiation, blanching, drying, and the like for the GABA-enriched plant and the like as required, dried powder of the cruciferous plant, the cut pieces, and the juice, containing GABA in a high concentration and maintaining green color, is obtained. Food material, medicine material, and feed made of the cruciferous plant containing GABA in a high concentration are obtained.

Abstract: The present invention relates to a preparation for stimulating or enhancing an immune system comprising one or more agents that stimulate T-lymphocytes in vivo. Such a preparation can be sued in the prophylaxis and/or treatment of a medical condition. The invention further relates to a preparation for use in a pharmaceutical or food product and to a preparation for medical use.

Abstract: This invention provides different compositions extracted from Ginkgo biloba leaves. Said compositions comprise new active components. This invention also provides a method of preparation of the compositions and individual components of said compositions. Finally, this invention provides various uses of this composition.

Abstract: This invention relates to an effective intervention plan. In one aspect, the invention relates to the treatment of various symptoms, conditions or diseases, such as diarrhea, constipation, congestion, eczema, asthma, fatigue, muscle weakness, tension and spasms, irritable bowel syndrome, swelling, anxiety, multiple chemical sensitivities, moderate to excessive and moderate to severe symptoms due to food allergies, sensitivities and intolerances, bloating, pain, headaches, leaky gut, hypersensitivity, sleep difficulties, severe under weight, eating disorders, obsessive, compulsive disorders, panic attacks, sensory sensitivities, Alzheimer's disease, acid refulx, irritability, delayed motor skills, delayed social skills, autism, PDD, infantile spasms and seizures by withholding for a period of at least 5 days all foods except for root crops.

Abstract: A process for manufacturing black leaf tea that looks and feels like orthodox processed tea but has the liquor characteristics of a fuller fermented CTC processed tea. The process involves withering a first supply of freshly plucked tea leaves, macerating the withered leaves, allowing the macerated withered leaves to ferment to produce macerated dhool, withering a second supply of freshly plucked tea leaves, mixing the macerated dhool obtained from the first supply of leaves with the withered leaves obtained from the second supply of leaves, rolling the mixture, allowing the rolled mixture to ferment, and drying the fermented mixture to yield black leaf tea.

Abstract: A machine for injecting fluid into a meat product has a frame and a meat injection station on the frame. An elongated conveyor is mounted on the frame for carrying a meat products towards and through the injection station. A motor is on the frame for operating the conveyor. A meat injection head on the frame is located at the injection station and includes a plurality of downwardly extending fluid injection needles. A fluid reservoir is mounted on the frame and is connected to a pump, with the pump also being connected to the needles. The motor is connected to a power train for moving the needles into and out of a meat product while it is being moved through the injection station by the conveyor. A bypass control circuit is on the frame and is connected to the pump and the reservoir for diverting fluid moving towards the needles from the pump in the reservoir when the needles are out of the meat product.

Abstract: A method of pasteurizing in-shell chicken eggs by heating eggs until a central portion of the yolks of the eggs is at a temperature between 128° F. to 138.5° F. That temperature is maintained and controlled for times within parameter line A and parameter line B of FIG. 1 and sufficient that any Salmonella species present in the yolk is reduced by at least 5 logs but insufficient that an albumen functionality of the egg measured in Haugh units is substantially less than the albumen functionality of a corresponding unpasteurized in-shell egg.

Abstract: The present invention includes puffed-food starch material snack, in particular starch material from grains, having an improved crispy texture and a more aesthetic appearance and methods for preparing them. In general terms, the products are snack chips, cakes, crackers or the like, made from food starch material. Preferably, the starch material is provided primarily in the form of individual kernels or pellets of a cereal grain, such as rice, corn, wheat, rye, oats, millet, sorghum, barley, buckwheat, or mixtures thereof. According to a method of making the puffed food starch material product of the present invention, a puffing chamber is provided having inner surfaces and a chamber volume. A bulk amount of the food starch material is placed into the puffing chamber. The bulk amount of food starch material is caused to volumetrically expand.

Abstract: A method for producing a food product including a solid casing coating at least one stuffing in a coextrusion device including a coextrusion die fed with a proteic base and a stuffing material. The method including forming in a first section of the die the casing which solidifies via a thermic effect. The first section being longitudinally traversed by at least one hollow needle for transferring the stuffing, one hollow needle per stuffing material, and penetrating into a second section of the die. Stuffing the second section of the die including the solid casing formed in the first section of the die with the stuffing material coming out of the hollow needle traversing the first section. Recovering the product, including the external casing filled with the stuffing material, at the outlet of the die.

Abstract: This invention generally relates to solid condiments comprising a base solid and a dosing liquid and, in particular, is directed to solid condiments which are free flowing, dry to the touch, and provide desirable color, flavor and/or aroma accents to foods, as well as methods for the preparation of the subject condiment compositions. When the base solid comprises salt, the preferred salt base solid component of a condiment of the invention comprises sodium chloride, potassium chloride, MSG and mixtures thereof. When the base solid comprises sugar, the preferred sugar base solid components comprise at least one monosaccharide, disaccharide or nonnutritive sweetener.

Abstract: Composite food having a gelling agent, selected from gelatin, egg white, modified waxy maize starch, whey protein concentrate, modified potato starch, gellan gum, and rennet casein, and a flavoring and/or texturing component, uniformly distributed throughout, selected from nonfat dry milk, butter, enzyme modified cheese, BBQ seasoning blend, cheddar cheese, sugars, milk protein concentrate, vinegar, and partially hydrogenated soybean oil, with the remainder of the composite made up primarily of water. The composite food product is substantially solid and self-sustaining at ambient temperature.

Abstract: A method for production of pectin that includes hot water extraction from a root vegetable under weak acidic conditions of pH 3.8-5.3 and pectin produced by the method, as well as a method for production of acidic protein food products that includes addition of the pectin to acidic protein food products, and acidic protein food products produced by the method.